Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of endogenous anterior uveitis in at least 1 eye.~* The presence of \> 10 cells in the anterior chamber of at least one eye, and a flare score of \> 2 in that same eye.~* Age 2 years or older on day of consent.~* Negative urine pregnancy test on Day 0 for females of childbearing potential who are not at least 1 year post-menopausal or surgically sterilized.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Presence of endogenous anterior uveitis diagnosed for \> 2 weeks prior to enrollment in the study.~* Presence of intermediate uveitis, posterior uveitis or panuveitis in either eye.~* Instillation of any topical corticosteroid or NSAID in the study eye within 7 days of instillation of study drug.~* History of glaucoma or clinically significant ocular hypertension in the opinion of the Investigator involving an IOP ≥ 21 millimeters mercury in either eye.~* History of steroid-induced elevation of intraocular pressure.~* Any confirmed or suspected active viral, bacterial or fungal keratoconjunctival disease in either eye.~* History of glaucoma or clinically significant ocular hypertension in the opinion of the Investigator involving an intraocular pressure (IOP) \> 21 mmHg in either eye.~* Corneal abrasion or ulceration in either eye.~* Pregnancy or lactation.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Durezol (Type: EXPERIMENTAL): Difluprednate 0.05% ophthalmic emulsion, 1 drop in study eye, 4 times a day for 14 days, followed by a 14-day tapering period
- Pred Forte (Type: ACTIVE_COMPARATOR): Prednisolone acetate 1.0% ophthalmic suspension, 1 drop in study eye, 8 times a day for 14 days, followed by a 14-day tapering period

Based on this trial design, predict the completion outcome and termination type (if applicable).